<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751163</url>
  </required_header>
  <id_info>
    <org_study_id>008</org_study_id>
    <nct_id>NCT03751163</nct_id>
  </id_info>
  <brief_title>Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma</brief_title>
  <official_title>Randomized, Controlled, Double-blind Study of Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess the effectiveness of oral tranexamic acid in combination with hydroquinone
      cream in the treatment of melasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydroquinone (HQ) is considered the gold standard depigmenting agent for melasma,
      nevertheless, many patients are recalcitrant to this treatment.

      Recent studies have shown that tranexamic acid, a plasmin inhibitor, can prevent UV-induced
      pigmentation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2016</start_date>
  <completion_date type="Actual">April 2, 2017</completion_date>
  <primary_completion_date type="Actual">April 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline mMASI Score at week 12</measure>
    <time_frame>Baseline, week 2, 12, 24</time_frame>
    <description>modified Melasma Area and Severity Index (mMASI) score was performed by rating darkness and area of involvement of 4 areas of the face (forehead, right malar, left malar, chin)
Scoring system: A, Area of involvement rated 0 to 6: 0 indicates absent;
1, &lt;10%; 2, 10% to 29%; 3, 30% to 49%; 4, 50% to 69%; 5, 70% to 89%; 6, 90% to 100%. D, Darkness rated 0 to 4: 0 indicates absent; 1, slight; 2, mild; 3, marked; 4, severe. b Total mMASI score range is 0 to 24 and calculated by adding scores for 4 areas of the face.
Forehead (0.3xAxD) + Right Malar (0.3xAxD) + Left Malar (0.3xAxD) + Chin (0.1xAxD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Melanin index</measure>
    <time_frame>Baseline, week 2, 12, 24</time_frame>
    <description>difference in pigmentation readings between involved and adjacent uninvolved skin, was measured using a mexameter.
Mexameter is a simple, rapid, and completely non-invasive instrument which measures skin pigmentation. The device has a probe which is gently pressed on the skin and painlessly records the level of pigmentation using a range of 1-1000, with 1 corresponding to white and 1000 to black.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Melasma</condition>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Oral Product</intervention_name>
    <description>Encapsulated tranexamic acid 250 mg</description>
    <arm_group_label>Study</arm_group_label>
    <other_name>TA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroquinone 4% Cream</intervention_name>
    <description>Hydroquinone 4% Cream</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study</arm_group_label>
    <other_name>HQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sunscreen</intervention_name>
    <description>Sunscreen SPF 30</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study</arm_group_label>
    <other_name>Sun Protection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Encapsulated placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate melasma (subject with mMASI score of 5 to 7.9),

          -  severe melasma (subject with mMASI score â‰¥ 8),

          -  willing to follow up for 6 months.

        Exclusion Criteria:

          -  pregnant women,

          -  nursing women,

          -  women on exogenous hormones

          -  current treatment with blood thinners,

          -  had a history of thrombosis,

          -  had an abnormal kidney function,

          -  use of topical hydroquinone within 3 months of study enrollment,

          -  use of topical steroids, vitamin A analogs, chemical peels within 1 month of study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Nahla Shihab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>melasma</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>hydroquinone</keyword>
  <keyword>mMASI</keyword>
  <keyword>mexameter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Hydroquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

